Retrospective study of weekly paclitaxel-cetuximab (WPC) in unselected patients (p) with recurrent/metastatic head and neck squamous cell carcinoma (RM-SCCHN)

Date

09 Oct 2016

Session

Poster display

Presenters

Isabel Pajares Bernad

Citation

Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376

Authors

I. Pajares Bernad1, J. Mártinez Trufero2, L. Calera Urquizu2, A. Cebolleo de Miguel2, R. Pazo Cid2, M. Lanzuela Valero3, M.J. Agsustín4, E. Millastre2, C. Santander Lobera2, M. Alvarez Alejandro2, N. Gimeno5, M. Malo Yague6, Y. Llorente7, A. Antón Torres2

Author affiliations

  • 1 Department Of Medical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 2 Department Of Medical Oncology, Hospital Miguel Servet, Zaragoza/ES
  • 3 Department Of Radiotherapy, Hospital Miguel Servet, Zaragoza/ES
  • 4 Department Of Pharmacy, Hospital Miguel Servet, Zaragoza/ES
  • 5 Department Of Medical Oncology, Hospital Royo Villanova, Zaragoza/ES
  • 6 Hematology Department, Hospital Ernest Lluch, Calatayud/ES
  • 7 Supportive Care, Arrabal centre, Zaragoza/ES
More

Resources

Background

WPC is an active treatment in RM-SCCHN, specially for unfit p not candidates to platinum. There are limited data so far about pronostic factors (PFs) in real-life practice.

Methods

Outcome data (Response and survival) along with PFs analysis of RM-SCCHN p treated in our centre with weekly paclitaxel (80 mg/m2) and Cetuximab (400/250 mg/m2) were retrospectively reviewed.

Results

148p were treated with WPC between January 2008 and July 2014. Female 15p (10,3%).Median age 62 years (38-87). Location: larynx 44p (29,7%), oral cavity 44p (29,7%), oropharynx 26p (17,6%), hipopharynx 11p (7,4%) and other 25p (15,6). Previous platinum-based therapy: 103p (69,6%) as initial treatment for localized stage, 31p (20,9%) for recurrent/metastatic disease. Stage: 101p (68,2%) unresectable/advanced disease, 9p(6,1%) metastatic disease and 38p (25,7%) both . Median number cycles: 9(1-27). 64p (43,2%) received cetuximab maintenance. Response rate (RR): 70p (47.3%) objetive response (OR)(complete + partial), 30p (20.3%) stable disease (SD), 48p (32.4%) progressive disease (PD). Median overall survival (OS) was 10 months(m) (95%CI;8.31-11.69) and progression free survival (PFS) was 7 m (95%CI;5.88-8.12). Analyzed PFs: Age, Sex, ECOG, Comorbidity index (CI)(ACE27 and Charslton CI), location, RR, stage, and albumin (Al), hemoglobin(Hb) and magnesium (Mg) serum levels were analyzed at baseline and monthly during therapy until PD or death. PD, basalAl level 1, Charslton CI >3, ECOG >1, previous disease free interval ≤ 20 m, Al basal level< 3gr/dl, Hb and Mg decrease. In MA, both PD and a 10% or less decrease in serum Mg levels were the only independent PFs for poor OS.

Conclusions

OS and PFS of a non-selected population of RM-SCCHN p treated with WPC was similar to that reported in a previous phase II trial, and comparable to platinum based treatment.Decrease of Mg levels during WPC therapy might be a prognostic biomarker that could be tested in prospective trials.

Clinical trial identification

Legal entity responsible for the study

Isabel Pajares Bernad

Funding

Department of Medical Oncology. Miguel Servet University Hospital

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings